Videos

Barbara Burtness, MD, discussed strategies for managing skin reactions and MET-driven edema in head and neck cancer treated with subcutaneous amivantamab.

Laura Alder, MD, discussed how her team at Duke monitors and educates patients for immune-related toxicities while receiving tarlatamab for brain metastases.

Hans Lee, MD, said it is only a matter of time before bispecific antibodies move into the newly diagnosed multiple myeloma setting.

In this segment, Isabel Curtin, LCSW, discusses the emotional and practical challenges that patients and families may face while navigating relapsed/refractory multiple myeloma and multiple lines of therapy.

In this opening segment, Samantha Shenoy, NP, introduces the From All Angles discussion and is joined by Elizabeth Bohannon, who shares her experience living with multiple myeloma, and Isabel Curtin, LCSW, who provides a psychosocial and supportive care perspective.

Experts emphasize that ongoing communication, whether from an academic or community oncology standpoint, is key for providing optimal multiple myeloma care.

Laura Alder, MD, discussed how tarlatamab’s intracranial activity compared with chemotherapy and radiation options for brain metastases in small cell lung cancer.

The discussion turns to the TOPAZ-1 study design and its long-term efficacy update.

Cell therapy will eventually become a part of the therapeutic strategy for newly diagnosed multiple myeloma, according to Joshua Richter, MD.

Laura Alder, MD, outlined the 3 objectives behind a retrospective analysis evaluating tarlatamab’s efficacy and safety in patients with SCLC and brain metastases.

Experts outline how certain practices may have an “incomplete understanding” of where the multiple myeloma field is today.

The phase 1b PRISM study is assessing the ability of ruxolitinib/retifanlimab to reinvigorate the tumor microenvironment in immune-resistant RCC.

Experts discuss the roles that telemedicine and outpatient programs can play in increasing access to novel cellular therapies among those with multiple myeloma.

In the first debate round of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator Rachna T. Shroff, MD, presents a patient with Child-Pugh A, BCLC stage C disease and bulky tumor burden, asking each team to defend a frontline regimen.

The panel discusses the timing of systemic therapy alongside locoregional treatment in intermediate-stage hepatocellular carcinoma (HCC), focusing on the EMERALD-1 results.

Edward S. Kim, MD, MBA, explained how City of Hope leverages AI tools to help community oncologists match patients with multidisciplinary clinical trials.

Toxicity management for patients who receive CAR T-cell therapy for multiple myeloma is improving, according to Marco Davila, MD, PhD.

Yu-Wei Chen, MD, MS, discussed research on ARNT expression patterns in RCC and potential implications for HIF-1β targeting therapies like NEO-811.

Academic clinicians have an incumbent role to improve access to novel cellular therapies, according to Marco Davila, MD, PhD.

Following the presentation of the real-world sequencing analysis, the faculty discuss how these findings align with their own clinical experience treating relapsed/refractory multiple myeloma (R/R MM).

Dr. Mansi Shah presents a multinational real-world analysis evaluating how BCMA-directed CAR-T cell therapies and BCMA bispecific antibodies are being used in routine clinical practice for patients with relapsed/refractory multiple myeloma (R/R MM).

Additional work is needed on a “significant population that develops lung cancer without a tobacco history,” according to Edward S. Kim, MD, MBA.

Patrick Borgen, MD built Brooklyn's breast cancer program from 47 patients to 8000. Now he and Joshua Feinberg, MD discuss what surgery looks like next.

In the concluding scientific discussion, Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla reflect on how emerging clinical evidence is shaping the future role of BCMA-directed therapies in relapsed/refractory multiple myeloma (RRMM).

In the second case-based discussion, Dr. Binod Dhakal and Dr. Prerna Mewawalla examine treatment considerations for an older patient with relapsed/refractory multiple myeloma (RRMM), multiple comorbidities, prior anti-CD38 exposure, and limited suitability for CAR T-cell therapy.

The faculty open the Between the Lines discussion by framing why advanced biliary tract cancer (BTC) remains a difficult-to-treat malignancy with rising incidence.

Joshua Richter, MD, and Marco Davila, MD, PhD, focused on real-world CAR T-cell therapy outcomes in multiple myeloma.

Kim Stravers, an end-of-life doula and educator, outlined how training and certification standards vary across end-of-life doula organizations.

Goutham Vemana, MD, discussed navigating regional access logistics, insurance coverage, and patient assistance programs to deliver intravesical gemcitabine in NMIBC.

Joshua Richter, MD, and Marco Davila, MD, PhD, discussed what are some optimal candidates for CAR T-cell therapy in multiple myeloma.